Software companies join e-pedigree forces

Software firm Ross Systems and supply chain company SupplyScape have announced a partnership to provide a software solution that allows pharmaceutical manufacturers to track their product through the supply chain, meeting regulatory and trading partner obligations.

An e-pedigree is an electronic certified chain of custody detailing each distribution of a drug, from the manufacturer, through acquisition and sale by any wholesaler or re-packager, until final sale to a pharmacy or other person administering or dispensing the drug.

Using Ross' Enterprise Resource Planning (ERP) solution, drugmakers such as PrecisionDose, a US Food and Drug Administration (FDA) registered repackager of pharmaceutical products, upload specific lot and shipping information into SupplyScape's e-pedigree application, which then verifies, certifies and transmits the pedigree, and provides automated, cost-effective pedigree authentication and tracking through the supply chain.

"We purchased the Ross ERP solution to have a complete system for managing our operations with total control and visibility into quality, product cost and profit, and tracking of materials throughout our production and warehouse operations," said Robert Koopman, president of PrecisionDose.

"We purchased SupplyScape e-Pedigree software because of its ability to fully integrate with the Ross ERP solution software, willingness to assist us with the validation of the software, and the quality and ease of tracking for electronic pedigree."

SupplyScape claims its e-pedigree reliably addresses both the diverse pedigree requirements and the varied operations of pharmaceutical companies and repackagers.

"In one standard solution, SupplyScape e-Pedigree reliably addresses both the diverse pedigree requirements and the varied operations of pharmaceutical companies and repackagers," said Shabbir Dahod, president and CEO of SupplyScape.

"Through SupplyScape's partnership with Ross, our mutual customers like PrecisionDose gain robust pedigree traction quickly and cost effectively to meet their FDA regulatory obligations, while realizing significant return on investment."